Nona Biosciences and Umoja Biopharma Collaborate to Advance Next-Gen CAR-T Cell Therapy Development

Nona Biosciences, a global biotech leader, has announced a collaboration with immunotherapy company Umoja Biopharma to develop novel CAR-T cell therapies. The partnership leverages Nona’s fully human heavy chain-only antibody (HCAb) technology and Umoja's VivoVec™ platform to create off-the-shelf treatments that enhance the reach and effectiveness of CAR-T therapies in oncology and autoimmune diseases. This innovative approach could significantly reduce immunogenicity and enhance the versatility of CAR designs due to HCAb's compact and simplified structure.

Nona's Harbour Mice® platform and its NonaCarFx™ CAR-function-based antibody screening will be combined with Umoja's gene delivery technology to develop new in vivo CAR-T cell drug candidates. Leaders from both companies expressed optimism about how the collaboration could create transformative, life-saving treatments for patients.

Nona specializes in developing monoclonal antibodies, with the Harbour Mice® platform offering both classical and heavy chain-only antibody formats. Umoja’s in vivo gene delivery tech empowers the patient’s immune system to target and eliminate diseases, positioning this partnership as a pivotal moment in the evolution of CAR-T therapies.